


## FTISADTSK acetate

<b>Cat. No.:</b>	HY-P3146A
<b>Molecular Formula:</b>	C <sub>44</sub> H <sub>72</sub> N <sub>10</sub> O <sub>18</sub>
<b>Molecular Weight:</b>	1029.1
<b>Sequence Shortening:</b>	FTISADTSK
<b>Target:</b>	Drug Metabolite
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Sealed storage, away from moisture
	Powder    -80°C    2 years
	-20°C    1 year



\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (48.59 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
<b>1 mM</b>	0.9717 mL	4.8586 mL	9.7172 mL
<b>5 mM</b>	0.1943 mL	0.9717 mL	1.9434 mL
<b>10 mM</b>	0.0972 mL	0.4859 mL	0.9717 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM)<sup>[1]</sup>.

### REFERENCES

[1]. Bults P, et al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016;88(3):1871-1877.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA